<DOC>
	<DOC>NCT01820767</DOC>
	<brief_summary>Use of Paricalcitol in stage Vd Chronic Kidney Disease patients, over the effect of inflammatory and oxidative stress parameters.</brief_summary>
	<brief_title>Paricalcitol Over Inflammatory Parameters on Chronical Kidney Disease Patients</brief_title>
	<detailed_description>Use of Paricalcitol in stage Vd Chronic Kidney Disease patients using a permanent catheter due to haemodialysis; over the effect of inflammatory and oxidative stress parameters. This study uses paricalcitol (vitamin D) versus atorvastatin versus paricalcitol plus atorvastatin treatments.</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>Vd CKD patients using haemodialysis during 3 or more months. Tunnelizedbearer permanent catheters on haemodialysis at last 6 months previous at the beginning of the study. . Kt stable, over 45 litres on both sexs. Patients in treatment wiht atorvastatin Patients without infectious or inflammatory processes over 8 weeks. Two consecutive PTH &lt; than 400 pg/ml; Ca&lt;10.2 and P &lt;7.0 mg/dl. Patients &gt; 18 years. Pregnant women. Patients hospitalized 4 weeks before the beginning of the treatment. Immunosuppressor intake.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>Vd-stadium.</keyword>
	<keyword>Inflammatory patterns</keyword>
	<keyword>Paricalcitol</keyword>
	<keyword>Atorvastatin</keyword>
</DOC>